Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers by Demetris, AJ et al.
.--
I· 
I 
i 
I 
( 
r· 
r 
American Journal of Pathology. Vol. 132. No.3. September 1988 
Copyright © American Association of Pathologists 
Antibody-Mediated Rejection of Human Orthotopic 
Liver Allografts 
A Study of Liver Transplantation Across ABO Blood 
Group Barriers 
A. JAKE DEMETRIS,· MD, RON JAFFE,§ MB, BCh, 
A. TZAKIS,:j: MD, GLENN RAMSEY,II MD, 
S. TODO,:j: MD, STEVEN BELLE,II PhD, 
CARLOS ESQUIVEL,:!: MD, RON SHAPIRO,:!: MD, 
BERND MARKUS,:!: MD, 
ELIZABETH MROCZEK,§ MD, 
D. H. VAN THlEL,t MD, GREG SYSYN, 
ROBERT GORDON,:!: MD, 
LEONARD MAKOWKA,:j: MD, PhD, 
and TOM STARZL,:j: MD, PhD 
A clinicopathologic analysis of liver transplantation 
across major ABO blood group barriers was carried out 
1) to determine if antibody-mediated (humoral) rejec-
tion was a cause of graft failure and if humoral rejec-
tion can be identi6.ed, 2) to propose criteria for estab-
lishing the diagnosis, and 3) to describe the clinical and 
pathologic features of humoral rejection. A total of 5 1 
(24 primary) ABO-incompatible (ABO-I) liver grafts 
were transplanted into 49 recipients. There was a 46% 
graft failure rate during the first 30 days for primary 
ABO-I grafts compared with an 11 % graft failure rate 
for primary ABO compatible (ABO-C), crossmatch 
negative, age, sex and priority-matched control pa-
tients (P < 0.02). A similarly high early graft failure 
rate (60%) was seen for nonprimary ABO-J grafts dur-
THE EARLIEST demonstration that immune serum 
was capable of producing hepatic damage was re-
ported by Pearce in 1904. 1 He found that when agglu-
tinating serum from rabbits (sensitized by injection of 
dog red blood cells) was infused into dogs, hepatic in-
farcts, liver failure, and death were observed. David-
sohn et al2 described a similar phenomenon in mice 
using hemolytic sera. 
In the early years of renal transplantation, attempts 
to cross major ABO blood group barriers often, but 
not invariably, resulted in poor allograft survival. 3 
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ing the first 30 days. Clinically, the patients experi-
enced a relentless rise in serum transaminases, hepatic 
failure, and coagulopathy during the first weeks after 
transplant. Pathologic examination of ABO-I grafts 
that failed early demonstrated widespread areas of 
geographic hemorrhagic necrosis with diffuse intraor-
gao coagulation. Prominent arterial deposition of an-
tibody and complement components was demon-
strated by immunotlourescent staining. Elution studies 
confirmed the presence of tissue-bound, donor-speci6.c 
isoagglutinins within the grafts. No snch deposition 
was seen in control cases. These studies confirm that 
antibody mediated rejection of the liver occurs and al-
lows for the development of criteria for establishing 
the diagnosis. (Am] Patholl988, 132:489-502) 
This poor graft survival was due to antibody-mediated 
("hyperacute") rejection. The pathophysiologic 
mechanisms underlying this phenomenon were de-
scribed by Starzl and coworkers in the 1960s.4-6 The 
precipitating event, namely, the binding of preformed 
isoagglutinins to the graft vasculature, which ex-
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presses the ABO antigens, results in complement acti-
vation, neutrophilic exudation, vessel damage (vascu-
litis), diffuse intraorgan thrombosis (ie, single organ 
diffuse intravascular coagulation), and consequent ac-
tivation of the fibrinolytic system with hemorrhagic 
necrosis of the graft. That other presensitized states 
and various nonimmunologic causes of graft damage 
such as donor or recipient sepsis could cause a similar 
clinicopathologic syndrome was suggested, and 
termed a graft "Shwartzman" reaction.4 
Liver allografts have been thought to be somewhat 
resistant to primary humoral or hyperacute rejection. 
The explanations offered for this observation include 
the dual vascularity of the liver, secretion of blocking 
antigen, and Kupffer cell removal of immune com-
plexes.7,8 Clinical experience9,IO and recent animal 
studies I 1,12 suggest that, while liver allografts may be 
resistant to hyperacute rejection, they may not be to-
tally spared from such catastrophic events. To docu-
ment the existence of this event in clinical material 
the authors retrospectively analyzed material relative 
to this important question. 
There are many difficult factors to be considered 
when undertaking such an analysis. First, previous 
studies have failed to demonstrate primary humoral 
rejection of livers grafted into patients with a positive 
cytotoxic crossmatch.1 3 Moreover, immunopatho-
logic studies have relegated antibodies to a "minor" 
role in liver allograft rejection.14 Furthermore, as was 
described for renal grafts, prior sepsis in the recipient 
or donor4 and preservation injurylS can produce a 
syndrome that is both clinically and pathologically 
similar to primary humoral rejection. Cellular rejec-
tion is easily recognizable on pathologic examination. 
It is characterized by a predominantly mononuclear 
portal tract inflammation with infiltration beneath 
the endothelium of portal veins and into bile ducts, 
which show evidence of damage. 
An analysis ofliver grafts transplanted across major 
ABO blood group barriers was undertaken because a 
state of presensitization is known to exist (isoaggluti-
nins), a deleterious clinical course following such 
transplants9 has been reported, and a likely cause for 
the decreased graft survival in such cases is antibody-
mediated rejection. 
Materials and Methods 
Patient Selection 
Index Cases 
All patients who received an ABO incompatible 
liver graft (non-O to 0, AB to non-AB, B to A or A to 
B) between 1981 and 1987 at the University of Pitts-
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burgh were studied. These patients were subdivided 
into patients receiving primary ABO incompatible 
(ABO-I) grafts and patients receiving secondary or ter-
tiary ABO-I grafts, where primary is the first graft and 
secondary the next, and so on. The reason for subdi-
viding these patients was the fact that patients receiv-
ing secondary grafts experience a higher rate of com-
plications that affect the analysis. Age, sex, and prior-
ity status of the primary ABO-I index cases were 
included in the analysis. Priority status refers to the 
condition of the patient before transplantation and is 
based on a numerical scoring system. Priority 1 is a 
patient at home without assistarice, 2 is at home with 
assistance, 3 is hospitalized, 4 is hospitalized with 
complications, 5 is hospitalized in the intensive care 
unit (ICU), and 6 is ICU with ventilator support. 
Control Cases-Group I 
The first group of controls was selected on the basis 
of the time of initial transplantation by OLT number. 
All patients at the University of Pittsburgh receive a 
sequential OLT number. For example, if a pediatric 
patient received a primary ABO-I graft on 11-19-86 
and was given OLT number 960, the immediate prior 
and consecutive pediatric patient (eg, OLT 959 and 
961) receiving a primary ABO compatible (ABO-C) 
graft served as controls. Therefore, each index patient 
had two controls unless the ABO-I index patients were 
close or consecutive by OL T number. When this oc-
curred a single case was used as a control for two index 
cases. The control patients were included in the analy-
sis regardless of the availability, or the results of, the 
T warm lymphocytoxic crossmatches, which were 
performed using the standard complement dependent 
cytotoxicity assay. Crossmatches are performed rou-
tinely for kidney allograft recipients because when 
they are strongly positive, a high probability for hyper-
acute kidney rejection exists. The same is not true for 
liver allograft recipients. Age, sex, and priority status 
of the control patients were also included in the 
analysis. 
The numerical OLT method of selecting control 
cases was chosen to compensate for variable handling 
of patients over a number of years. The most signifi-
cant of the factors are the technical advances in the 
surgical procedure, the large number of new surgeons 
at a training institute such as Pittsburgh, and the use 
of venous bypass which has reduced the intraopera-
tive use of blood products and therefore have less of 
an effect on the immune status of the recipient sera. 
No controls were included for the secondary ABO-
I grafts. These controls were omitted because of the 
difficulty in choosing appropriate cases when factors 
such as the cause of primary graft failure, priority sta-
Vol. J 32 • No. J 
tus, presence of sepsis, hypotension, and sensitization 
from the initial graft are taken into consideration. 
Control Group II 
The second group of controls was selected after an 
initial comparison of the index cases with OLT num-
ber control cases (Group J). It was found that primary 
ABO-I cases experienced a much higher incidence of 
early «4 weeks) graft failure secondary to sub massive 
or massive hemorrhagic necrosis, with/out vascular 
thrombosis. ABO-C, cytotoxic crossmatch negative 
patients, transplanted over the same period of time, 
who also lost their grafts within the first several weeks, 
were chosen. These were chosen as histo- and immu-
nopathologic controls because it was hypothesized 
that all early graft failures may have a similar histo-
and immunopathologic appearance, unrelated to 
prior sensitization. Cytotoxic crossmatch positive 
controls with early graft failure were excluded from 
the analysis, because presensitization may have con-
tributed to graft failure and complicated the analysis. 
Patient Demographic Data 
There were a total of 24 patients (5 adults, 19 chil-
dren) who received primary ABO incompatible 
(ABO-I) hepatic grafts. Twenty-five patients (7 adults, 
18 children) received ABO-I secondary, tertiary, or 
quartinary grafts. Two adult patients received two 
consecutive ABO-J grafts (secondary and tertiary). In 
total, 51 ABO-I grafts were transplanted into 49 pa-
tients. 
The OLT number control cases (Group I) con-
tained 38 patients (10 adults, 28 children) who re-
ceived ABO compatible (ABO-C) primary grafts. The 
early graft-failure pathologic controls (Group II) con-
sisted often patients who received ABO-C grafts who 
experienced early graft failure ( <2 weeks). 
A total of 62 cases (24 index and 38 group I control 
cases) were included for statistical analysis and will be 
referred to as the study group. The study group was 
primarily pediatric (average age for pediatric patients 
was S. 8 ± 4.8 years and for adults was 45.3. ± 9.0 
years), with 48 (77%) under the age of 18 at the time of 
transplantation. Among the primary ABO-I patients, 
83% were under the age of 18, compared with 74% 
of the controls (P> 0.05). The overall distribution of 
priority scores did not differ significantly between the 
primary ABO-I and control group I cases (P> 0.05). 
Routine Pathologic Studies 
All pathologic specimens from ABO-J grafts (pri-
mary and nonprimary), Group I, and II controls were 
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reviewed. There were eight hepatectomy specimens, 
four autopsy livers, and 46 needle biopsy specimens 
available in the primary ABO-I group. Pathology 
specimens from aU livers other than the ABO-I graft in 
a particular patient were omitted from consideration. 
Histologic sections were routinely stained with hema-
toxylin and eosin (H & E), trichrome, and periodic 
acid-Schiff with diastase digestion. Selected sections 
were stained for fibrin. 
Particular attention was given to the histopatho-
logic findings of plat let-fibrin thrombi, vasculitis, con-
gestion, hemorrhage, neutrophilic infiltration, and 
ischemic necrosis. 
Immunopathologic Studies 
All failed allograft and autopsy tissues from ABO-I 
and from control group II that experienced early graft 
failure were stained for the presence ofIgG, IgM, 19A, 
Clq, C3, C4, and fibrinogen using both a direct im-
munofluorescent and an indirect immunoperoxidase 
technique. 16 
Elution Studies 
Frozen graft tissue (2 to 5 g) was minced by hand 
or through the use of a Kinematica Polytron tissue' 
homogenizer. The tissue was then washed four times 
in 6% bovine albumin at 4 C. Heat elution was per-
formed at 56 C for 15 minutes into 2 to 3 ml of albu-
min, then the tissue was centrifuged at 4500g for 5 
minutes. The supernatant was tested by hemaggluti-
nation against AI, B, and 0 red blood cells, with read-
ings at immediate spin, 30 minutes at 37 C, and poly-
specific antiglobulin. The immunoglobulin class of 
the eluted antibodies was determined by use of anti-
IgG antiglobulin reagent and treatment with dithio-
threitol to inactivate IgM. The last wash solution 
which tested negative for ABO antibodies served as a 
control. Testing was performed without knowledge of. 
the donor and recipient ABO types. 
Review of Operative and Clinical Course 
A detailed review of pertinent clinical events was 
achieved by consultation with the surgical team in-
volved in each of the cases combined with a review of 
the patients chart. Special attention was focused on 
other reasons for graft failure, including assessment of 
donor organ, operative complications, and other co-
morbid states (eg, sepsis, hypotension) that may have 
contributed to poor graft function or failure. Addi-
tionally, pertinent observations as to the early appear-
492 . DEMETRIS ET AL 
ance of the graft after reperfusion and the presence of 
postoperative bleeding were recorded. 
Case Evaluation 
The cases were evaluated after all available infor-
mation including donor complications, preservation 
injury, technical or intraoperative complications, 
clinical course, routine and immune pathology, and 
elution studies were available. Because there are cur-
rently no criteria available for the diagnosis of primary 
humoral liver allograft rejection, the following classi-
fication was used: 1) No apparent humoral event-
There was no clinically detectable graft malfunction, 
no pathology specimen, or insufficient evidence of 
pathologic changes in biopsy specimens. 2) Probable 
humoral event-There was clinical evidence of early 
(less than I week) graft malfunction, pathologic evi-
dence of graft damage, tissue deposition of antibody 
and complement, but confounding influences that 
may have contributed to graft damage (eg, bacterial 
seeding of infarcted tissue, hypotension, prolonged 
preservation). 3) Primary humoral rejection-There 
was clinical evidence of early (less than 1 week) graft 
malfunction, graft failure, pathologic evidence of 
multiple graft infarcts, tissue deposition ofimmuno-
globulin and complement, no evidence of confound-
ing clinical or pathologic observations, and demon-
stration of donor-specific isoagglutinins in tissue elu-
ates from the failed graft. 
Results 
Graft Survival Analysis 
All patients were followed for a minimum of 30 
days (up to 2141 days). Among control group I, 4 
( 11 %) of grafts failed within 30 days, compared with 
11 (46%) of the primary ABO-I cases (P < 0.05). The 
odds ratio of graft failure within 30 days of trans plan-
tation in strata defined by each of the independent 
variables (gender, age group, and priority status at the 
time of transplant) was calculated (data not shown). 
Odds ratios statistically significantly (P < 0.05) greater 
than 1, implying greater risk of early graft failure 
among those receiving incompatible grafts than 
among those receiving compatible grafts, were found 
for females, pediatric patients and for patients in the 
hospital (not in the ICU) at the time of transplanta-
tion. 
A multivariate model, the logistic regression model, 
was used to determine whether there was an effect of 
ABO compatibility on graft failure, simultaneously 
adjusting for the effect of gender, age, and priority sta-
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tus. When the full model was fit, a statistically signifi-
cant effect (P < 0.05) was found for ABO compatibil-
ity, but not for any of the other independent variables. 
The adjusted odds ratio was 11.8 with a 95% confi-
dence interval of(2.5, 56.6). This implies that, adjust-
ing for gender, age group, and priority status, the odds 
of a recipient suffering graft failure within the first 30 
days of liver transplantation is about 12 times greater 
among those receiving ABO-I grafts than among those 
receiving ABO-C grafts. None of the other indepen-
dent variables (age, sex, or priority status) examined 
were found to be statistically significant (P > 0.05), 
adjusting for case or control status. 
Individual Case Analysis 
A synopsis of the clinical, serologic, and routine and 
immune pathologic and elution studies of the primary 
ABO-I cases is shown in Table 1. A similar analysis of 
. control group I and II cases is shown in Tables 2 and 
3, respectively. 
Index Cases 
Follow-up to this writing has shown that ten (42%) 
ofthe primary ABO-I grafts are still functional. Four-
teen patients (58%) have experienced graft failure and 
were retransplanted or expired. Four were classified as 
primary humoral rejection due to Preformed isoagglu-
tinins. Humoral mechanisms were thought to playa 
significant, if not the primary, role in graft failure in 
eight others. Recurrent hepatitis B was responsible for 
graft failure in one case. In the remaining case, al-
though evidence of humoral involvement was pres-
ent, graft failure was temporally too remote (147 days) 
from the operation to implicate humoral mechanisms 
as the primary reason for graft failure. No correlation 
was detected between the underlying liver disease and 
graft failure. 
Only eight of the 27 (30%) ABO-I secondary or ter-
tiary grafts are still functional. Nineteen of the grafts 
(70%) had to be retransplanted or the patient expired, 
with an average graft survival of 27 days. The causes 
of graft failure were quite similar to that seen in the 
primary ABO-I group, with a high incidence of hem-
orrhagic necrosis in the first several weeks, with or 
without vascular thrombosis. However, the incidence 
of infections, priority status, and other complicating 
clinical circumstances was higher (data not shown). 
OLT# Control Cases (Group I) 
Twenty-four (63%) of the primary ABO-C OLT# 
control grafts are presently functioning. However, in 
contrast to the ABO-I primary index cases, the aver-
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Table 2-Clinicopathologic Summary of ABO Compatible Primary Liver Allografts (Control Group 1)* 
Graft 
Age Donor Recipient Graft survival 
OLT# (yrs) Sex ABO ABO status (days) Cause of graft failure or patient death 
192 10.5 M A A Function 2141 
195 44.6 M 0 0 Failed 439 Sepsis, recurrent CAH-B 
197 39.0 M 0 0 Failed 905 Chronic rejection 
201 4.5 M 0 0 Failed 33 HAT with liver abscesses 
239 5.9 F A A Function 1773 
246 2.4 M A A Failed 26 Adenovirus and chronic rejection 
444 3.4 F A A Function 926 
446 5.2 F A A Function 924 
472 7.8 F A AB Failed 672 Chronic vascular rejection, duct obstruction 
478 5.9 F 0 0 Function 853 
535 1.2 F A A Function 699 
537 2.6 M 0 0 Failed 119 HAT with hilar necrosis 
546 10.3 M 0 0 Function 678 
551 4.1 F A 'A Function 667 
594 0.9 M 0 0 Failed 29 HAT with hilar necrosis, abscesses, CMV 
604 9.6 M A A Failed 86 Hilar abscess with vein-abscess fistual and 
hematoma 
610 6.6 M A A Function 589 
619 11.8 F 0 0 Failed 54 Perioperative stroke, lymphoma in liver at 
autopsy 
678 1.5 F 0 0 Failed 41 Aorta-enteric fistula with sepsis 
692 4.9 F 0 0 Function 473 
720 0.8 F A A Failed 275 HA stenosis, sepsis from chotangitis 
732 7.4 M 0 0 Function 418 
827 49.3 M 0 0 Function 305 
830 53.0 M AB AB Function 247 
870 16.1 M B B Failed 10 Uncontrolled rejection 
874 2.2 F 0 0 Function 253 
946 54.8 F 0 0 Function 169 
949 16.1 M B B Function 165 
958 2.8 M A A Function 104 
964 5.0 M 0 0 Failed 71 HAT with organ infarction 
1010 36.1 F A A Function 151 
1012 37.1 M A A Function 148 
1013 37.7 M 0 0 Function 76 
1017 53.4 F A A Function 73 
r 1088 7.8 M A A Function 58 
1096 13,4 M 0 0 Failed 3 IschemiC necrosis, technical problem at 
arterial anastomosis 
1112 6.8 M A A Function 35 
1122 54.6 F 0 0 Function 189 
• All patients had a negative T-werm Iymphocytotoxic crossmatch or results were not available except for OL T# 619 who had a positive crossmatch. 
CAH-B, chronic active hepatitis B; CMV, cytomegalovirus; Function, functional graft; Fail, graft failure; HAT, hepatic artery thromboSis. 
age survival offailed grafts in this group was 197 days. cause of failure in the remaining patient was determined 
Additionally, the causes of graft failure differed sig- to be the result of preservation injury. 
nificantly from that seen in the primary ABO-I group 
(see Tables land 2). 
Routine Gross and Light Microscopic Pathology 
Early Graft Failure/Pathology Controls (Group II) Index Cases 
Ten patients receiving ABO-C primary grafts, who The majority of the pathologic samples were taken 
had a negative T warm cytotoxic crossmatch experi- as a result of the early onset of graft malfunction. Pre-
enced graft failure within the first two weeks. Eight grafts and postimplantation biopsies were available in five 
failed from hepatic artery or iliac graft thrombosis or patients. The following description is a summary of 
mural dissection, which according to the operating sur- the pathologic findings present in the primary ABO-I 
geon, was explainable on technical grounds. One patient livers. 
had no portal vein for anastomosis, requiring an alterna- Preimplantation samples generally showed mlDl-
tive venous anastomosis that was unsuccessful. The mal to no pathologic alterations, other than mild focal 
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Table 3-Clinicopathologic Summary of Group II Controls' (Early Graft Failures) 
Graft 
survival Eluate 
OLT# (days) Clinical events Pathology findings IF ipex react. Summary 
220 4 No recipient portal Bridging periportal Neg Neg Technical problem with portal 
vein available for necrosis, no vein anastomosis with 
anastomosis microvascular ischemic graft injury 
lesions 
271 4 Technical problem Periportal Neg NO Ischemic graft injury from 
with arterial hemorrhage, focal technical problem at 
anastomosis central necrosis arterial anastomosis 
steatosis 
273 9 Portal vein thrombosis Portal vein thrombosis Neg NO Portal vein thrombosis, 
and rejection severe cellular probably technical and 
rejection and severe cellular rejection 
necrosis 
284 5 Primary non function Extensive periportal Neg NO Injury probably the result of 
necrosis. no preservation 
vascular 
thrombosis 
identified 
498 5 Technical problem HAT with multiple Neg NO Technical problem at arterial 
with arterial infarcts and anastomosis 
anastomosis with bacterial seeding 
HAT NO 
522 4 Primary non function Necrotic arterial wall Neg T schnical. arterial wall 
with focal with little necrotic at anastomosis 
reaction with 
infarcts 
716 12 Technical problem at Arterial wall Neg Neg Technical problem resulting 
arterial dissection, bacterial in arterial dissection and 
anastomosis seeding and diffuse bacterial seeding of liver 
necrosis 
8081 8 Difficult arterial HAT. moderate acute Wkpos Neg Technical arterial problem 
anastomosis cellular rejection, with HAT and cellular 
central ballooning rejection 
836 15 Arterial thrombosis HAT with hilar Neg NO HAT. probably technical 
necrosisfabscess 
1068 2 Iliac vascular graft Multiple subcapsular Neg ND Arterial thrombosis 
technical. thrombOSis Infarcts. arterial 
thrombosis. hilar 
necrosis 
• All patients had a negative T-warm Iymphocytotoxic crossmatch, except for OL T 808. which was weakly positive. 
HAT, hepatiC artery thrombosis; IFfipex. Immunofluorescencefimmunoperoxidase; NO. not done; Neg, negative. 
hepatocellular swelling. Samples taken 2 to 6 hours 
postimplantation showed a rather impressive cluster-
ing of neutrophils, fibrin deposition, and red blood 
cell sludging in the sinusoids (Figure 1). This was seen 
in association with focal hemorrhage into the space of 
Disse, focal hepatocellular cytoaggregation, or single 
cell acidophilic necrosis. Biopsy samples l' to 2 days 
later continue to showed the above changes, but small 
clusters of hepatocytes with coagulative necrosis, in-
creased red cell congestion, and hemorrhage were 
seen also. Small portal arteries mayor may not show 
fibrinoid degeneration. A mild neutrophilic portal ex-
udate may begin to appear, with focal duct prolifera-
tion as signs of regenerative attempts. At this stage, the 
histologic changes can be difficult if not impossible to 
separate from those of prolonged preservation injury 
(unpublished observation). Thereafter, a progressive 
patchy geographic hemorrhagic infarction of the or-
gan ensues. The early progression of the changes may 
or may not be detected in biopsies because of sam-
pling problems, but once the process is widespread, 
coagulopathy, submassive or massive necrosis and he-
patic failure manifest, necessitating retransplantation. 
An examination of failed ABO-I grafts revealed en-
larged (up to twice the preimplantation weight) hem-
orrhagic organs, mottled with random areas of necro-
sis, with or without large vessel thrombosis. The 
capsule had actually ruptured in OT# 615. 
Microscopically, focal fibrinoid necrosis, inflamma-
tory vasculitis, and thrombosis of some medium and 
small-sized arteries was seen in only four cases (Fig-
ures 2 and 3). More prevalent arterial and venous 
findings included plump reactive endothelial cells 
with lumenal platelet and neutrophil sludging, focal 
fibrin layering around their circumference or fibrin 
masses extending in a flamelike fashion into the lu-
.".,.,.. 
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figure 1-Hlstologic appearance of jiver biopsy specimens from ABO-! grafts taken early after reperfusion. a-Postimpiantation biopsy taken approxi-
mately 2 to 4 hours after reperfusion, with diffuse sinusoidal neutrophilic and red blood eel congestion. (H & E, X300) b-Biopsyafter 1 day, note the 
small areas of coagulative necrosis in the lobule (arrows), mild portal neutrophilia, and red blood eel congestion. (pt, portal tract, H & E, x300) A biopsy on 
day 5 showed progressive infarction. Findings in the failed allograft specimen (Ol T 721) are illustrated in FigUres 4, 5, 6A, 6B. 
mens from an attachment to a partially disrupted vas-
cular wall (Figure 4). The parenchyma in all cases 
showed severe and widespread geographic areas of 
hemorrhagic necrosis intermixed with neutrophils, of-
. ten with no particular zonal distribution (Figure 5). 
The hepatic cords often were compressed and the he-
patocytes necrotic, leaving ghosts of the normal archi-
tecture and cells. 
Control Cases (Groups I and II) 
Biopsy and failed graft. specimens from group I, 
showed little resemblance to the findings described for 
the ABO-I cases. The only exception is that a few of 
the biopsies obtained in the first several postoperative 
days contained the focal sinusoidal neutrophilic clus-
ters, focal congestion and single acidophilic necrosis 
of hepatocytes. The severity of this change was less 
than that seen in the ABO-I group. 
Failed grafts from control group II with arterial 
thrombosis and hilar abscesses, demonstrated intra-
parenchymal areas of necrosis with abscess formation, 
which appeared reminiscent of the necrosis seen in the 
ABO-I livers. Necrotizing or inflammatory cell vascu-
litis was not found, however, nor was there significant 
staining for immune deposits. 
Cases not included in this study but reviewed for 
comparison in which there was donor or recipient sep-
sis or both, or prolonged preservation injury showed 
similar changes to those seen in the biopsies obtained 
from the ABO-I grafts in the first several days. Im-
mune staining in these cases were negative. 
Immunoflourescence/Immunoperoxidase 
ABO-I Cases 
All cases thought to represent primary humoral re-
jection or probable humoral rejection demonstrated 
the presence of focal but intense deposition of IgM 
and C lq, with lesser amounts ofC3, usually in arterial 
walls, from hepatectomy specimens (Figure 3). Focal 
IgG deposits were found in only one case. Patchy sinu-
soidal and venous staining also could be seen but it 
was much less impressive than the deposits in the ar-
teries, which reflects intrahepatic distribution of the 
ABO antigens. 17 Ultrastructural studies revealed elec-
tron-dense deposits in the vasculature with overlying 
fibrin (Figure 6). In general, the arterial deposits were 
not uniformly distributed throughout the liver. In 
fact, some subcapsular sections were negative, while 
those taken closer to the hilar demonstrated impres-
sive arterial deposition. Sequential staining of a bi-
opsy at day 6 in OT 196 showed diffuse sinusoidal, 
arterial and venous deposition of IgM. IgG. and C3, 
with little cellular infiltrate. The autopsy specimen 2 
days later showed only focal IgM and C 1 q, with multi-
ple geographic hemorrhagic infarcts. 
Control Cases (Group II) 
Deposition ofIgM and IgG in arterioles was seen in 
one case, with a weakly positive cytotoxic crossmatch. 
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Figure 2-Failed allograft (OL T 1093) 4 days after transplantation. a-Note the necrotic and thrombosed hepatic arteries in a pertal triad. The cellular 
detail is lost because the liver is infarcted and hepatocyte nuclei no longer visible (H & E, x 120) b-The thrombi and the entire thickness of the arterial 
wall stained intensely with PAS after diastase digestion. (PAD-D, x 120) This contrasts marl<edly with the H & E which was hemorrhagic and infarcted but did 
not catch the eye. c-The thrombi and the arterial walls demonstrated depcsition of IgM. The C1q stain was identical. (immunoperoxidase IgM, 
X120) d-The thrombi and the arterial walls demonstrated depesition of C1 q. The IgM was identical. (immunoflounescence, C1 q, x 120) 
Figure 3-Hepatectomy specimen from failed non primary ABO-I graft (17 days pesttransplant), most of which showed changes identical to the primary ABO-
I grafts. a-Note the severe proliferative and neutrophilic arteritis (H & E, :>(450) with depesition of IgM in the arterial wall (b, immunoperoxidase IgM, 
X300). Staining for C1 q and C3 were also present. 
",' 
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All other cases were uniformly negative. Sinusoidal 
staining for Clq and fibrinogen were positive fre-
quent!v. particularly in and around the central vein 
region. in this group and in the ABO-I group. This 
was considered to be nonspecific as a result of leak-
age through the damaged sinusoidal wall or Kuptfer 
cell phagocytosis. Although not included in this 
study. several cases of IgM leakage into the wall of 
medium-sized arteries of grafts \vith thrombosis at 
the arterial anastomosis. as :l result of technical 
problems. has been seen. In general. however. the 
deposits were less intense. and were accompanied 
by the leakage of ,nher serum components such as 
tibri nogen (unpublished observation). In addition. 
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Figure 4-Vascular pathology in ABO-I grafts. a-Arterial and b-ve-
nous lesions from failed primary ABO-I graft (OLT 721). Note the partial 
disruption of the vascular wall with attachment of a fibrin thrombus (H & E, 
X300). A spectrum of findings from sequential samples of the same case is 
shown in Figures 1, 4, and 5. c-Arterial lesion in non primary ABO-l 
graft that failed 3 months posttransplant from intrahepatic infarcts and ab-
scess (H & E, X120). Note the organized, web-like thrombus. One could 
easily appreciate the possibility of progression from a lesion similar to that 
illustrated in a. 
elution studies failed to demonstrate donor-specific 
antibodies. 
Elution Studies 
Eluates of tissue from failed primary ABO-f allo-
grafts that were thought to represent primary humoral 
rejection all showed reactivity against donor ABO an-
tigens (N = 4). Analysis of the reactivity using dithio-
thrietol and anti-IgG antiglobulin reagent gave results 
characteristic of IgM antibody class, identical to that 
found within the tissues. 
Eluates of three primary ABO-C early graft failures 
(group II controls), were negative for isoagglutinins. 
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Figure 5-Low power IH & E, :(100) view of 
failed ABO-I graft showing diffuse hemorrhagic 
necrosis. A portal tract, with little to no inflam-
mation is seen at the middle right of the photo-
graph. 
Eluates were not studied in cases classified as probable 
humoral rejection. 
Clinical Observations 
A clinical diagnosis of "hyperacute" rejection of a 
liver allograft, that is, a graft that after initial adequate 
reperfusion, becomes cyanotic, mottled, flaccid, and 
fails to produce bile, was not made in this group of 
patients. The primary ABO-I grafts in each case were 
reperfused adequately and produced bile when in-
spected by the operating surgeon before abdominal 
closure. The only clinical clue to future complications 
in the immediate reperfusion period was difficulty in 
achieving hemostasis. In retrospect this may have 
been due to activation of the fibrinolytic and kinin 
cascades as a response to extensive intrahepatic coag-
ulation. The events of the first several days after trans-
plantation were more revealing. 
During this period, the cases of primary humoral 
rejection most often had a relentless rise of serum 
transaminase values. An initial reperfusion value for 
AL T and AST in the 400 to 500 IU range on day 1 
followed by values ranging from 2000 to 10,000 IU 
on subsequent days signaled a catastrophic event. An-
giograms and percutaneous liver biopsies were per-
formed to rule out arterial thrombosis or other identi-
fiable causes of graft malfunction. Arterial angio-
graphy in one case was particularly striking. It 
demonstrated a markedly narrowed arterial tree, 
thought to be the result of diffuse arterial spasm. Biop-
sies in general showed the changes described above 
and were initially interpreted as "preservation in-
jury." The rise in transaminases was followed by se-
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vere bleeding and hepatic failure, necessitating re-ex-
ploration, retransplantation or both. The appearance 
of the organs at retransplantation was similar to the 
appearance of kidneys undergoing "hyperacute" re-
jection. They were enlarged, mottled, and cyanotic. 
The gross intraoperative appearance of one of the 
grafts (OLT# 615) was particularly impressive. The 
organ was massively enlarged, cyanotic, had a capsu-
lar rupture, and was bleeding from the surface. 
This clinical course is somewhat different from that 
seen in organs damaged from prolonged preservation. 
In general, initial reperfusion transaminase values are 
high (1000 to 2000 IU) in preservation injury, but 
show a downward trend over the next several days 
rather then a relentless upward progression, as was 
seen in the primary ABO-I grafts with humoral rejec-
tion. 
ABO Profiles of Primary ABO Incompatible Grafts 
The Qrofiles of the primary ABO-I grafts are shown 
in Table 4. A noticeable difference in the survival rates 
of 0 recipients who received non-O grafts was evident. 
The majority (six of ten) of the primary ABO-I that 
remained functional were from this combination. The 
same trend is true of non primary ABO-I grafts in that 
six of eight of the functional grafts were non-O donors 
to 0 recipients. 
Discussion 
The results of this study show that liver allografts 
are susceptible to primary humoral rejection when 
major ABO blood group barriers are violated. The di-
.," 
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Figure 6-Ultrastructural appearance of immune deposits in vein wall from failed ABO-I graft. a-Note the electron dense deposits with thin overtying 
layer of fibrin (arrows, X5000). b-Higher power detail of electron-dense deposits (X15,OOO). 
agnosis, however, should be limited to cases in which 
the following tetrad of findings are all present: 1) early 
graft failure (usually within 2 to 4 weeks), with no al-
ternative clinical or pathologic explanation; 2) consis-
tent routine light and immunoflourescent micro-
scopic findings (see results); 3) demonstration ofa pre-
sensitization state in tbe recipient, and 4) presence of 
donor-specific antibodies in an eluate from the failed 
graft. Strict adherence to these criteria will prevent ov-. 
erdiagnosis. because a similar clinical course and 
hemorrhagic necrosis of the graft may occur in a vari-
ety of settings. 
Previously, the diagnosis of "hyperacute" or anti-
body-mediated rejection of liver grafts has been hin-
dered for several reasons. First. as in renal transplanta-
Table 4-ABO Profiles of Donor/Recipient for Primary ABO-I 
Grafts According to Graft Status 
Donor to recipient 
combination 
non-OloO 
AloB 
StoA 
ABteA 
ABteS 
TOTAL 
Total no. 
grafts 
8 
9 
2 
5 
24 
Functional 
grafts 
6 
2 
10 
Failed 
grafts 
2 
7 
1 
4 
14 
tion, a sufficient number of cases is necessary for com-
parison analysis. Second, there are a multitude of 
factors that can contribute to early graft failure such 
as "preservation injury," donor or recipient cardio-
vascular instability or sepsis, and operative difficul-
ties. Third, the pathologic correlates of the above 
mentioned factors have not been described well. 
Presently, we are in a better position to critically 
analyze the causes of early graft failures with the ~x­
pectation of reasonable conclusions due to the follow-
ing factors: 1) improved graft survival with fewer early 
graft failures as a result of advances in operative tech-
niques, patient selection, and immunosuppressive 
protocols; 2) better understanding of the pathologic 
correlates of other graft complications, and 3) a suffi-
cient number of cases are available to compare graft 
survival and the spectrum of pathologic findings. 
This combined clinicopathologic analysis has led to 
the conclusion that liver gratis are susceptible to early 
graft failure as a result of primary antibody mediated 
damage. Based on the data presented. thinking had to 
be redirected as to the immunopathologic mecha-
nisms that may be responsible for liver allograft rejec-
tion because antibodies were previously thought to 
play only a minor role. Unlike kidney and heart grafts. 
the term "hyperacute" rejection is probably not the 
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best term for this phenomenon because it was not im-
mediately recognizable by the operative surgeon 
shortly after reperfusion. A more generically applica-
ble term is primary humoral rejection. The reasons 
for this difference are probably the same as those 
offered for explaining the seeming resistance of liver 
allografts to the phenomenon. The documentation of 
such a diagnosis requires a detailed analysis of each 
case because other factors mentioned can also lead to 
a similar biologic phenomenon. 
Early allograft failure secondary to hemorrhagic ne-
crosis may be seen as a consequence of damage before 
or during preservation,18 ischemic ("shock liver") or-
gans l9 with or without vascular thrombosis, or when 
there is coexistent sepsis (particularly gram negative) 
in the donor or recipient. The observation that preser-
vation injury, hypoxic, and septic- or endotoxin-in-
duced liver damage resembles primary humoral rejec-
tion is not surprising if one considers the underlying 
pathophysiology. The primary insult in each of these 
disorders is endothelial cell damage,18-20 resulting in 
release of tissue thromboplastins and exposure of un-
derlying collagen. Vasospasm, platelet plugging, and 
initiation of the intrinsic and extrinsic clotting cas-
cades and the subsequent activation of fibrinolytic 
and kinin systems ensues. This single-organ DIC-syn-
drome may result in systemic bleeding complications, 
as was seen in many of the patients. While the initial 
triggers of the single organ Shwartzman or DIC reac-
tion may vary, the subsequent cascade of events that 
result in tissue damage are probably similar. The key 
to determining the cause of graft failure when such a 
situation is encountered is to identify the initial event. 
The study of ABO-I grafts was instrumental in pro-
viding the major clue to the triggering event of the sin-
gle organ Shwartzman reaction. The authors had al-
ready discovered that graft survival was significantly 
worse when crossing ABO barriers,9 that the patient 
(by definition) is presensitized, and that humoral re-
jection was a likely cause of the poorer survival. The 
further documentation of clinical events, pathologic 
correlates, isoagglutinin deposits and elution studies 
was needed to confirm these suspicions and to confi-
dently separate the grafts with humoral rejection from 
those with other causes of failure. 
Difficulties in establishing a pathologic diagnosis of 
suspected humoral rejection can be encountered. 
These arise when severe tissue damage is accompa-
nied by nonspecific leakage of immunoglobulin and 
complement, particularly in subcapsular infarcts, or 
because of the sometimes patchy distribution of im-
mune deposits in antibody mediated rejection. Care-
ful interpretation of the im m unoflourescent findings 
for distribution (arterial) and specificity (selective de-
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position) will assist in the differentiation of nonspe-
cific leakage from antibody mediated rejection. The 
observation of the focal nature of the deposits has sev-
eral possible explanations. Antibody-mediated dam-
age may be the initial trigger of the cascade of events 
early after transplantation, but becomes degraded and 
not detectable when searched for in the failed graft, 
days or weeks later. This scenario was seen in OLT 
196 (see results). Also, the heaviest deposition may oc-
cur in vessels that are first exposed to the circulation 
and explain the greater likelihood of finding deposits 
in the perihilar vessels in some of the cases. 
Therefore, the diagnosis of humoral rejection may 
be difficult to establish before organ failure and resec-
tion. Clinical cues that signal the onset of this phe-
nomenon include dramatic elevations of hepatic en-
zymes in the first postoperative week combined with 
bleeding and progressive liver failure, all in the ab-
sence of any explanation by other factors. Documen-
tation then requires tissue sampling (wedge biopsy is 
optimal). Histologic findings that should make one 
suspect antibody mediated rejection are outlined in 
the results section. Immune staining for antibody and 
complement components should be performed and, 
if positive, followed by tissue eluate analysis, which 
can be done on a small frozen-tissue sample. The final 
diagnosis must be based on a complete clinicopatho-
logic analysis, as was done in this study, and fulfill the 
criteria offered at the beginning of the discussion sec-
tion. 
An interesting trend was noted in the donor and re-
cipient ABO profiles of surviving ABO-I grafts. 
Twelve of the 16 ABO-I grafts that are still functional 
were from non-O donors to 0 recipients. Although 
the numbers are small and the implications serious, 
crossing the ABO barrier in this direction may be safer 
than with other combinations. Hypothetically, this 
observation is consistent with the immunoglobulin 
class response patterns seen in the rejected organs. 
The immune response of group A and B subjects to 
ABO antigens is predominantly IgM in nature, 
whereas group 0 subjects respond with IgG anti bod-
ies. 21 In addition, children 5 to IS-years-old, who may 
be the most likely candidates to receive ABO incom-
patible grafts because of reduced donor availability, 
also have the highest levels ofIgM ABO antibodies of 
any age group,22 a finding consistent with the observa-
tion that the pediatric primary ABO-I cases presented 
with the most striking findings. This observation may 
or may not have significance for T warm lymphocyto-
toxic antibodies, which are IgG in nature. 
Finally, because it was found that humoral rejec-
tion of liver allografts is possible when ABO barriers 
are violated, a search must be made for the conse-
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quences of ignoring other presensitized states. A de-
tailed analysis of each case with strict adherence to the 
criteria outlined is essential, however. 
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